FDA: Diabetes drugs to include severe heart risk warnings

08/14/2007 | Washington Post (tiered subscription model), The

GlaxoSmithKline and Takeda Pharmaceutical Co. Ltd. have agreed to include "black-box" warning labels on their diabetes drugs to caution patients about the risk of heart failure caused by the drugs, the FDA announced Tuesday. The new labels, which recommend close monitoring of patients taking Actos and Avandia, are separate from previous reports that link Avandia to heart attacks.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC